GRYSKA DAVID W 4

What Happened
David W. Gryska, a director of Forte Biosciences, was granted 18,353 restricted stock units (RSUs) on May 29, 2026. The award is recorded as an acquisition-type derivative transaction at $0.00 per unit, meaning no cash was paid. Each RSU represents a contingent right to receive one share of Forte common stock if and when the RSUs vest.

Key Details

• Transaction date: May 29, 2026; Form 4 filed June 2, 2026. The filing does not indicate a late-reporting exception.
• Security and amount: 18,353 RSUs granted (derivative award), reported at $0.00 per unit.
• Shares owned after transaction: not specified in the information provided on this filing.
• Footnotes:
  • F1 — Each RSU equals the contingent right to one share of Forte common stock.
  • F2 — Vesting: 100% of the RSUs vest on the date of the first annual stockholder meeting occurring after May 29, 2026, provided the reporting person remains a service provider as defined in the plan.
• Transaction code: A (award/grant). No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context
RSU grants are common compensation for directors and executives and do not involve an immediate cash investment or sale. These RSUs only become actual shares if vesting conditions are met; they are therefore a potential future increase in share count rather than current insider buying or selling. This filing documents the grant; it does not on its own signal a personal cash commitment or immediate market activity.